How do pravastatin and atorvastatin work?
Both pravastatin and atorvastatin are statins. They lower LDL (“bad”) cholesterol by blocking HMG‑CoA reductase, an enzyme needed to make cholesterol in the liver. They can also modestly improve triglycerides and raise HDL (“good”) cholesterol.
What’s the main difference between them?
The biggest practical difference is potency and how strongly they typically lower LDL.
- Atorvastatin is generally considered more potent for LDL reduction than pravastatin at comparable doses.
- Pravastatin is usually chosen when a clinician wants a less potent statin effect or when a patient’s history suggests better tolerability with that option.
Do they differ in side effects or muscle risk?
Both drugs carry the same core statin risks, especially muscle-related side effects (myalgia, and rarely more serious muscle injury). Differences in real-world risk can vary person to person, but pravastatin is often perceived as having a somewhat lower muscle-interaction risk because of its metabolism, while atorvastatin is more likely to interact with other medications that affect drug levels.
How do they compare in drug interactions?
They differ in metabolism pathways, which affects interaction risk.
- Atorvastatin is metabolized more by liver enzymes involved in drug-drug interactions, so it can have more interaction concerns with certain antifungals, antibiotics, HIV antivirals, and other medicines that affect those enzymes.
- Pravastatin has fewer interactions for many patients because it uses different metabolic routes, so it may be easier to combine with other medications.
Are they used for the same conditions?
Yes. Both are used for similar cholesterol-related goals, such as:
- Lowering LDL cholesterol in people with hypercholesterolemia
- Reducing cardiovascular risk in appropriate patients
The choice usually comes down to how much LDL lowering is needed and the patient’s other medications and medical history.
Which one is “stronger” for lowering LDL?
In many clinical comparisons, atorvastatin achieves larger average LDL reductions than pravastatin. If a clinician needs aggressive LDL lowering, atorvastatin is often favored. If a moderate reduction is enough or there are interaction/tolerability concerns, pravastatin is often considered.
Is there a practical way clinicians decide between them?
Common decision drivers include:
- Target LDL reduction (bigger LDL lowering often points toward atorvastatin)
- Current medication list (interaction risk can influence the choice)
- Prior statin experience (if someone had issues on one statin, another may be tried)
- Liver disease considerations and overall risk profile
If you share your current dose(s), other medicines, and the reason you’re switching (e.g., LDL level, side effects, interactions), I can help interpret how that typically affects which drug is chosen.